Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. [electronic resource]
Producer: 20091022Description: 2479-87 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Camptothecin -- administration & dosage
- Cell Line, Tumor
- Drug Synergism
- Enzyme Inhibitors -- administration & dosage
- Female
- Histone Deacetylase Inhibitors
- Histones -- metabolism
- Humans
- Male
- Melanoma -- drug therapy
- Mice
- Mice, Nude
- Middle Aged
- Skin Neoplasms -- drug therapy
- Topoisomerase I Inhibitors
- Valproic Acid -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.